Evidence map›Paper›PMID 29623536›Full record

ArticleMolecular diversity2018

A practical multi-step synthesis of ethyl N-functionalized [Formula: see text]-amino benzimidazole acrylate derivatives as promising cytotoxic agents.

Christelle N'Ta Ambeu, Rémy Le Guével, Anne Corlu, Janat Akhanovna Mamyrbekova, Jean-Pierre Bazureau

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Christelle N'Ta AmbeuInstitut des Sciences Chimiques de Rennes (ISCR), UMR CNRS 6226, groupe COrInt, Université de Rennes 1 (UR1), Campus de Beaulieu, Bât. 10A, 263 Avenue du Général Leclerc, CS 74205, 35042, Rennes Cedex, France.
Rémy Le GuévelUniversité de Rennes 1, ImPACcell Platform, SFR Biosit, Bât. 8, Campus Villejean, 2 Av. du Prof. Léon Bernard, CS 34317, 35043, Rennes Cedex, France.
Anne CorluUniversité de Rennes 1, ImPACcell Platform, SFR Biosit, Bât. 8, Campus Villejean, 2 Av. du Prof. Léon Bernard, CS 34317, 35043, Rennes Cedex, France.
Janat Akhanovna MamyrbekovaLaboratoire de Chimie Bio Organique et Substances Naturelles (LCBOSN), Université Nangui Abrogoua (UNA), 02 BP 801, Abidjan, Côte d'Ivoire.
Jean-Pierre BazureauInstitut des Sciences Chimiques de Rennes (ISCR), UMR CNRS 6226, groupe COrInt, Université de Rennes 1 (UR1), Campus de Beaulieu, Bât. 10A, 263 Avenue du Général Leclerc, CS 74205, 35042, Rennes Cedex, France. jean-pierre.bazureau@univ-rennes1.fr.ORCID http://orcid.org/0000-0003-3053-3425

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A series of 16 new ethyl [Formula: see text]-amino benzimidazole acrylate derivatives 12(a-p) with a (2E)-s-cis/trans conformation and bearing two points of diversity was designed and synthesized by using a multi-step strategy (reductive amination, deprotection in acidic media and transamination) in moderate to good yields from ethyl 3-dimethylamino-2-(1H-benzimidazol-2-yl)acrylate (5) and monosubstituted N-Boc diamines (7a,7b) as starting building blocks. Products 12 were evaluated for their in vitro cytotoxic potential against six selected human cell lines (Huh7-D12, Caco2, MDA-MB231, HCT116, PC3 and NCI-H727). Compounds 12a, 12e and 12l exhibited selective and micromolar antitumor activities against Huh7-D12 and Caco2 cell lines.

Indexed as

AcrylatesAntineoplastic AgentsBenzimidazolesCytotoxinsCell LineCell Line, TumorCell SurvivalHumansAcrylatesAntineoplastic AgentsBenzimidazolesCytotoxinsBenzimidazoleCytotoxicityMicrowaveReductive aminationTransamination

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.